

Challenges of Tuberculosis in Iran

Abed Zahedi Bialvaei,¹ Mohammad Asgharzadeh,² Mohammad Aghazadeh,¹ Manouchehr

Nourazarian,³ and Hossein Samadi Kafil^{3,*}

¹Infectious and Tropical Disease Research Center, Tabriz University of Medical Sciences, Tabriz, IR Iran

²Biotechnology Research Center, Tabriz University of Medical Sciences, Tabriz, IR Iran

³Drug Applied Research Center, Faculty of Medicine, Tabriz University of Medical Sciences, Tabriz, IR Iran

*Corresponding author: Hossein Samadi Kafil, Assistant Professor, Drug Applied Research Center, Faculty of Medical Sciences Tabriz University of Medical Sciences, Tabriz, Iran. Tel: +98-9127184735, Fax: +984133364661, E-mail: Kafilhs@tbzmed.ac.ir

Received 2016 April 21; Revised 2017 January 12; Accepted 2017 January 18.

Abstract

Background: Despite the implementation of the national control program, tuberculosis is one of the greatest health problems in Iran. The prevalence of different strains in specific ethnic populations suggests that *Mycobacterium tuberculosis* transmission has been limited and restricted to close contact.

Objectives: In the present review, we describe the epidemiology of tuberculosis in Iran.

Methods: In this review article, databases including Scopus, PubMed, and Google scholar were used to search for the epidemiology of tuberculosis in Iran.

Results: Since 1996, tuberculosis incidence has been decreased as the national tuberculosis control program was established in Iran. However, due to the emergence of drug-resistant strains, recurrence of the disease, and association of tuberculosis with HIV pandemic, tuberculosis is becoming a health problem in Iran like many other parts of the world. Moreover, several other factors such as poverty, homelessness, inadequate access to health services, and lack of infrastructure in public health play an important role in worsening the situation. The distribution of the disease is not similar in all parts of Iran and it is higher in the western and eastern parts than the central areas.

Conclusions: Review of the studies revealed that levels of multidrug-resistant tuberculosis among new tuberculosis patients are increasing in Iran and the vaccination system needs to be reformed. Because of the increasing number of patients coming from neighboring countries with multidrug-resistant tuberculosis, this area needs more stewardship and control in order to prevent the outbreak of multidrug-resistant tuberculosis. Finally, by improving the healthcare system, it is trusted that a more noteworthy number of these patients will be cured in Iran.

Keywords: Epidemiology, Surveillance, Multidrug resistance, *Mycobacterium tuberculosis*

1. Background

Tuberculosis has claimed its victims throughout the history. Tuberculosis's notoriety as one of the most important bacterial terrors of humanity alongside typhoid, typhus, plague, cholera, and diphtheria has led to descriptors such as "the captain of all those men of death" and "great white plague". More than a decade after the declaration of world health organization (WHO) about the global health emergency of tuberculosis, it is still a major health concern worldwide (1). Tuberculosis occurs in every nation all around the world; but, the most noteworthy frequency is found in Africa and Asia, while lately, it has re-emerged as a major public health issue in Russia and other eastern European nations (2).

Considering the importance of tuberculosis, especially in developing countries such as Iran with a large number of Afghan immigrants, changes in age range, and growing population, it is necessary to acquire comprehensive

information about this disease in order to adopt appropriate control strategies and achieve WHO's goals. This type of information may include drug resistance, outbreak rate, underlying factors such as smoking and diabetes, socio-cultural factors, and mortality rate. Other factors that play an important function in the spread of tuberculosis are age, male gender, homelessness, immigration, asthma, smoking, family history of close contact with tuberculosis or human immunodeficiency virus (HIV) patients, making the outbreak of tuberculosis more likely in the impoverished provinces. We believe that the present review can provide comprehensive information regarding the epidemiology of *Mycobacterium tuberculosis* infection in Islamic Republic of Iran.

2. Objectives

In the present study, we describe the epidemiology of tuberculosis in Iran. In this review article, Scopus, Pubmed,

and Google scholar databases were used to study the epidemiology of tuberculosis in Iran.

3. Evidence Acquisition

In the literature review process, Scopus, Pubmed, and Google scholar databases were searched to study the epidemiology of tuberculosis, drug resistance, molecular epidemiology, multidrug-resistant tuberculosis, and HIV/tuberculosis co-infection in Iran.

4. General Status of Tuberculosis in Iran

With close attention to the fact that tuberculosis is still one of the biggest killers among the infectious diseases, Iran, like other countries of the world, uses a live attenuated vaccine [Bacille Calmette-Guerin (BCG)] and several antibiotics, which are essential to gain better understanding of the pathogenicity and virulence factors of *M. tuberculosis* (3). Due to the introduction of vaccination program in 1988 to immunize all children at birth, the incidence of tuberculosis in Iran reduced from 20,308 cases in 1990 to 15,545 cases in 2006 as well as the mortality rate declined from 2,358 cases to 1,839 cases per year. In addition, a comprehensive review has been conducted in Iran on directly observed therapy short-course (DOTS) program, and surveillance and laboratory quality assurance involving healthcare providers for controlling tuberculosis have been strengthened as well (4). The aim of this program is to be ascertained of patients' adherence to therapy by observing them to swallow each dose of medication (5). However, one important problem in carrying out the DOTS strategy by healthcare workers is the inconvenience of the patients in terms of obtaining the drugs from a health center frequently a week. Therefore, the performance of this strategy under the control of family members could be an alternative (5).

5. Incidence and Prevalence

The distribution of tuberculosis is not uniform; the incidence and prevalence of the disease are higher in the regions near the borderlines and lower in the central parts of the country (Figure 1). The borderline areas of Iran including the provinces of Sistan and Baluchestan, Golestan, Khorasan, East Azerbaijan, West Azerbaijan, and Kurdistan are endemic regions by giving 10% - 13% multidrug-resistant isolates among 141 TB cases per 100,000 (6).

It is currently estimated that over 2 billion people worldwide are exposed to *M. tuberculosis*, with over 8.7 million new infections in 2012, leading to 2.5 to 3 million cases

of mortality per year; this makes tuberculosis the foremost cause of death by infection (7). In Asia, it is not exactly known when tuberculosis initially spread. However, the prevalence of the disease in the continent was high until the end of the nineteenth century which remains so today. According to WHO's statistics in 2008, most of tuberculosis cases (34.1%) occurred in the south-east of Asia, leading to the death of about 1.3 million cases (8). Based on another report by WHO, in 2011, Iran had a lower incidence of tuberculosis (21 per 100,000 population) than all the neighboring countries (Turkey: 24 per 100,000, Iraq: 45 per 100,000, Armenia: 55 per 100,000, Azerbaijan: 113 per 100,000, Afghanistan: 189 per 100,000, and Pakistan: 231 per 100,000) (Figure 2) (9).


6. Tuberculosis Incidence Rates by Sex and Age

Across the world, tuberculosis is more common among men than women and happens more often in the adults with difficult occupations. In 2012, about 3 million out of 8.6 million cases of tuberculosis were women and 530,000 were under 15 year old children (10). According to Iranian studies, tuberculosis prevalence is also higher among males than females. This phenomenon may be due to the fact that men are more active in the community and more exposed to the carriers and risk factors of the disease such as cigarettes and narcotic substances. In the WHO's report in 2013, the male to female ratio was 1.1 in Iran (11). In the north of Iran, the incidence of tuberculosis is 1.6 times higher in men than women (10). Also, in Bandar Abbas (a southern city in Iran), pulmonary tuberculosis has been 2.5 times higher in men than women. In Kashan (a central city in Iran), 50.3% of the disease prevalence is seen among women. However, in Yazd, 53%; in Shiraz, 63%; in Zabol, 64%, and in Abadan 55% of cases have been observed among men (12).

7. Molecular Typing of *M. tuberculosis* in the Population

By the introduction of molecular epidemiological typing methods, described in the following, *M. tuberculosis*-related strains have been identified and characterized. Therefore, they are categorized in seven potential families, clades, or lineages, including Haarlem, Latin-American and Mediterranean (LAM), East-African-Indian, Beijing, X, T, and Central Asian families (13). One of the most important families is the Beijing family, in which the spread of drug-resistant tuberculosis is associated with the expansion of strains belonging to the family (14). Although the T family is the most frequent genotype among Iranian tuberculosis cases (15), recent studies have shown that Beijing,

Figure 1. A General View of the Prevalence of TB in Different Parts of Iran



Highlighted areas on the country borderlines show a higher prevalence rate.

Central Asian, and Haarlem genotypes are overrepresented among multidrug-resistant tuberculosis cases in the country (16, 17). However, because of low case notification rate and preferred migration of Afghan individuals to particular parts of Iran, it is not clear whether this genotype has been imported to the country after the massive migration of Afghans or it has been one of the circulating genotypes of *M. tuberculosis* in Iran (18).


8. Immigrants

Geographically, Iran is located in the south-west of Asia with the total land boundaries of 5,440 km. Iran has the population of 78 million and shares geographic borders with three countries in which, tuberculosis is endemic: Afghanistan, Iraq, and Pakistan. In addition, Iran is in a close association with other countries where tuberculosis is highly prevalent, i.e. China, India, Nepal, Bosnia, Bangladesh, Tajikistan, Sri Lanka, and Azerbaijan. Iran's Ministry of Health, along with some charities, has provided patients with free-of-charge treatments, which can be an explanation for the vast number of

tuberculosis-affected individuals in the area, because a number of refugees enter the country to benefit from such free treatment (19). During the past two decades, immigrants from neighboring countries have flooded to Iran. UN Refugee Agency stated that at the end of 2005, Iran had been the host of the third largest refugee populations in the world, with the total of 716,000 refugees (<http://www.migrationinformation.org>).

Recently, investigators have demonstrated intra-community transmission as the circulating strain of *M. tuberculosis* in different countries (20, 21). Generally, molecular epidemiology shows the predominance of certain families of *M. tuberculosis* in specific locations. In 2002, the number of affected patients per annum in the eastern Mediterranean region was reported as 630,000, with 136,000 annual deaths, among whom 43% were from Pakistan, 12% from Afghanistan, and 6% from Iran (Figure 3) (22). One of the most important immigrant populations in Iran is from Afghanistan. For example, the approximate number of recorded Afghan immigrants in Fars province (south of the country) is 200,000. However, because most of these immigrants are not recorded, this number seems

Figure 2. Estimates of TB Incidence, Prevalence, and Mortality in Iran, According to WHO's Report, During 1990 - 2013



Rates are per 100,000 population.

to be less than the half of the real number of these immigrants, comprising a flowing population with low income (18).

Most Afghans who migrate to Iran are men leaving their families in Afghanistan to come to Iran to look for a job. The average three years incidence of tuberculosis among the Afghan immigrants in Fars province was 82.6 per 100,000 populations, while according to the data from Ministry of Health; the incidence of tuberculosis among the Iranian population of Fars Province from 2000 to 2002 was 5.2 per 100,000, i.e. 16 times less than that among Afghans (22). Afghan patients include more than half of the multidrug-resistant tuberculosis cases in Iran, which reflects insufficient health services and surveillance infrastructure in their country (23). In a survey conducted by Farnia et al. the rate of reactivation versus recent transmission was evaluated among Afghan and Iranian relapse cases and the impact of Afghan immigrants on the national tuberculosis control program of Iran due to intra-community transmission between Afghan and Iranian tuberculosis cases was highlighted (24).

Based on a report by WHO, Republic of Azerbaijan is another country with a high tuberculosis incidence and multidrug-resistant tuberculosis burden (11). Azeri patients travel to the northwest of Iran for tuberculosis treatment (25). Because of the increasing number of patients referring from Republic of Azerbaijan to the region with




Figure 3. Contributions of the Countries to the Tuberculosis Burden in the Eastern Mediterranean Region

multidrug-resistant tuberculosis, there is a need for more stewardship and control of these patients in order to prevent the outbreak of multidrug-resistant tuberculosis in the region (25, 26). This finding supports the proposal for

a policy to screen all immigrants to Iran for tuberculosis, especially those from tuberculosis high-burden countries such as Azerbaijan, Pakistan, and Afghanistan. Therefore, positive patients would be subjected to anti-tuberculosis treatment before being allowed into the country (27).

9. Treatment Policy and Antibiotic Resistance

The treatment policy of tuberculosis in Iran involves the administration of isoniazid, rifampicin, pyrazinamide, and ethambutol for the first 2 months and administration of isoniazid and rifampicin for the next 4 months (28). For the treatment of multidrug-resistant disease in Iran, National Tuberculosis Program recommends a combination of kanamycin or amikacin, ethionamide, pyrazinamide, ofloxacin, and ethambutol or cycloserine in the initial phase, followed by ethionamide, ofloxacin, and ethambutol or cycloserine in the continuation phase for 18 months (29). However, some private practitioners in Tehran do not comply with these recommendations and the results of susceptibility testing are not always being used for selecting suitable second-line drugs (30).

Rifampicin has been found to be an effective anti-tuberculosis agent and its utilization has incredibly shortened the span of chemotherapy for the treatment of tuberculosis (31). It has also been demonstrated that the patients infected with rifampicin resistant strains will encounter a higher failure rate with short-course 6-month chemotherapy (32). These patients require treatment for at least two years while the treatment is 70 times more costly accompanied by much higher mortality rate (about 40% - 60%) (23). In different parts of the world, multiple types of mutations have been identified in rifampicin-resistant *M. tuberculosis* clinical isolates, most of which are 10 codon point mutations, while only a few isolates have insertion or deletion. Most frequently involved codons in mutation have been codons 526 and 531 in various parts of the world (33, 34).

The mutation in *rpoB* gene, which encodes the "beta" subunit of RNA polymerase, is almost exclusively associated with resistance to rifampicin (35). This mutation can be found in 96.1% of rifampicin resistant *M. tuberculosis* isolates and occurs in rifampicin resistance-determining region with 81-bp lengths corresponding to 507 - 533 amino acid residues (35). In an Iranian report, it was demonstrated that 28% of isolates were rifampicin resistant, which was still lower compared to many areas in Africa and Europe (51.9% - 68.9%) (36), while in the United States, about 13% of isolates from new tuberculosis cases have been resistant to one or more of the first-line anti-tuberculosis drugs and 1.6% of cases are resistant to both isoniazid and rifampicin, defined as multidrug-resistant

tuberculosis (37). Although multidrug-resistant tuberculosis in the re-treatment patients varies from 30% to 80% in different regions of the world (38), a study in Iran showed a notable success in the treatment of multidrug-resistant tuberculosis (39). In the same report, bacteriological cure occurred in 76.5% of the patients who were resistant to rifampicin and isoniazid (Table 1).

In the studies conducted in Iranian settings, drug resistance to streptomycin has been found to have the highest proportion among anti-tuberculosis drugs, followed by isoniazid with 23% resistance in new cases of tuberculosis (23, 40, 41). The high prevalence of streptomycin resistance isolates may be due to the previous usage of other aminoglycosidal drugs for the treatment of different infectious diseases, like brucellosis, which can result in cross-resistance (23). This high rate of streptomycin resistance has very important implications for tuberculosis control strategies since it would make treatment regimens less effective (40).

Isoniazid, one of the main agents in tuberculosis treatment, is a pro-drug that, via passive diffusion, enters the bacteria by enzyme catalase-peroxidase changes into an active form and paves the way for attacking several targets in the microorganism by free radicals. The previous observations have shown that after being exposed to isoniazid, tuberculosis bacillus loses its acid fastness property (42). The development of isoniazid resistance usually precedes resistance to rifampicin; therefore, resistance to isoniazid is considered a surrogate marker for multidrug-resistant tuberculosis (43). The increasing resistance to isoniazid is an alarming sign, which demonstrates further transmission of resistant strains in the community. Resistance to isoniazid is associated with a variety of mutations in several genes such as *inhA*, *KatG*, *kasA*, *oxyR-aphC*, and *ndh* (44).

Mutation in *katG* gene is the primary mechanism of isoniazid-resistance in many strains (45). *KatG* gene encodes protein catalase-peroxidase and mutation in this gene blocks or decreases the chemical activity. The frequency of primary drug resistance to isoniazid was 9.8% - 15% in a recent study (46). Also, in a report from the eastern region of Iran as well as in another study carried out in Isfahan and Tehran provinces, isoniazid-resistant *M. tuberculosis* isolates contained mutations in *KatG* gene with the mutation rate of 61%, 78%, and 61%, respectively (47, 48). The huge increment of isoniazid resistance in the last few years displays a vital need for the quick identification and effective management of isoniazid-resistant tuberculosis in Iran.

Pyrazinamide is also an imperative first-line medication utilized for the short-course treatment of tuberculosis in combination with isoniazid and rifampicin (49), because it is bactericidal to semi-dormant mycobac-

Table 1. Resistance to First-Line Drugs Among MTB Isolates from Different Parts of Iran^a

Province	Strains	Pan-Susceptible	Any Drug Resistance	INH	RIF	EMB	SM	Mono-Resistance	Multidrug Resistance	Reference
Tehran	85	68 (80.0)	17 (20.0)	6 (7.0)	7 (8.2)	6 (7.0)	14 (16.4)	11 (13.0)	6 (7.0)	(40)
Sistan-Baluchestan	59	49 (83.0)	10 (17.0)	5 (8.4)	3 (5.0)	3 (95.0)	8 (13.5)	7 (11.8)	3 (5.0)	(40)
Kermanshah	15	9 (60.0)	6 (40.0)	4 (26.6)	3 (20.0)	3 (20.0)	3 (20.0)	2 (13.3)	3 (20.0)	(40)
Hormozgan	48	42 (87.5)	6 (12.5)	3 (6.2)	2 (4.1)	2 (4.1)	4 (8.3)	4 (8.3)	2 (4.1)	(40)
Isfahan	45	43 (20.0)	2 (3.2)	2 (7.1)	2 (8.6)	0 (0.0)	1 (2.2)	0 (0.0)	2 (11.7)	(40)
East Azarbaijan	120	84 (70)	36 (30)	13 (10.83)	12 (10)	4 (3.33)	27 (22.5)	(ND)	6 (5)	(25)
Khorasan	105	74 (70.5)	1 (0.95)	1 (0.95)	0 (0.0)	0 (0.0)	27 (25.7)	(ND)	1 (0.95)	(56)

Abbreviations: EMB, ethambutol; INH, isoniazid; ND, not defined; RIF, rifampin; SM, streptomycin.

^aValues are expressed as No (%).

teria that are persistent in acidic-pH environments inside macrophages and not influenced by other anti-tuberculosis drugs (50). Due to the global emergence of multidrug-resistant tuberculosis, the rates of resistance to pyrazinamide are also growing (51).

10. Multidrug-Resistant Tuberculosis in Iran

Drug resistance of *M. tuberculosis* was perceived soon after the presentation of effective anti-tuberculosis agents in the late 1940s (52). Based on a nation-wide survey carried out in 1999, 10.9% of all the *M. tuberculosis* isolates tested for drug susceptibility were resistant to ≥ 1 anti-tuberculosis drug and 6.7% were resistant to both isoniazid and rifampicin (i.e. were multidrug-resistant strains of *M. tuberculosis*) (53). According to available data, the proportion of multidrug-resistant isolates in new tuberculosis patients is increasing in Iran, and about 3.7% of such cases are estimated to be multidrug-resistant strains (7). These isolates are considered as an emerging problem in many parts of the world. However, the epidemiology, prevalence, genetic diversity of multidrug-resistant tuberculosis genes, and mutations conferring drug resistance vary across Iran. A report published in 2000 showed that the primary resistance to a number of drugs became more frequent; the most resistance rate was against streptomycin, followed by ethambutol, and isoniazid (41). These characteristics were also confirmed by the results of a study from Turkey, in which the highest resistance was found against streptomycin (54).

Previous inadequate treatment is an important prognostic factor in the increase of multidrug-resistant tuberculosis in Iran. Most of the patients had been taking irregular anti-tuberculosis drugs for a long time, leading to failure in treatment (55). However, among the new patients diagnosed with tuberculosis, 5% normally have multidrug-resistant tuberculosis, which is an emerging problem of great importance to the public health of Iran. These isolates, resistant to both isoniazid and rifampicin with or

without resistance to other drugs, have caused concerns worldwide due to high mortality (56). Such cases are difficult to cure, requiring the use of second line drugs that are more expensive and poisonous than the first line regimens. It has also been demonstrated that individuals who have primary resistance and frequently experience failed treatment may become gradually more resistant and hard to cure (57). In this way, it is imperative to determine the distribution of resistance mutations at the level of every nation prior to molecular tests being presented for routine diagnostics (58).

A study from Iranian national research institute of tuberculosis and lung disease on drug resistance patterns of tuberculosis from 2003 to 2008 has shown that 2% of *M. tuberculosis* isolates from new cases were multidrug-resistant (59). Also, in a recent survey, 41 (16.3%) of 252 *M. tuberculosis* isolates collected from the patients of different parts of Iran, including five provinces, were resistant to at least one anti-tuberculosis drugs (40). This study indicated lower drug resistance rates in Iran than the studies conducted in Turkey, Iraq, and Pakistan with the drug resistance rates of 21.1%, 29.7%, and 64% respectively (15, 60). Recently, *M. tuberculosis* strains that are Extra-drug-resistant, i.e. they are tuberculosis strains resistant to at least three of the six classes of second-line drugs (para-aminosalicylic acid, fluoroquinolones, polypeptides, thioamides, aminoglycosides, and cycloserine), have been reviewed in Iran (61). However, at present, the number of Extra-drug-resistant tuberculosis cases in the nation is still low; but, the higher rate of tuberculosis cases comprising Multi drug resistant tuberculosis in the neighboring nations such as Pakistan, Afghanistan, and the countries of the former Soviet Union, underlying the probability that almost the same cases also exist in these countries (61).

11. Surveillance System

Continuous surveillance of the primary and acquired drug-resistance patterns of *M. tuberculosis* to assess the ef-

efficacy of the past chemotherapy regimens is important as the same as detecting errors in past treatments (62, 63). However, the absence of a comprehensive surveillance network and inadequacy of reliable prevalence studies in Iran make it difficult to evaluate the true extent of multidrug-resistant tuberculosis in the country (56). The present worldwide tuberculosis control paradigm mostly focuses on cutting transmission via primary case detection and effective therapy, while medical interventions are at the core of the global plan (64).

According to the WHO's report in 2006, it takes about 126 days in Iran to identify and treat smear positive pulmonary tuberculosis, and the diagnosis process is the most time consuming issue (Figure 4) (65). Fast and accurate diagnosis of tuberculosis plays an important role in preventing the transmission and mortality. Data have shown a significant relationship between delay in diagnosis and treatment of tuberculosis in prisons, which causes more transmission and mortality in patients in prisons compared to ordinary people (10).

Tuberculin skin test (TST) with purified protein derivative (PPD) as one of the cell-mediated immunity (CMI)-based tests has low specificity in the detection of tuberculosis infection (66). However, the ratio of positive purified protein derivative tests to number of patients who are tested in the studies is about 50% (10, 67). In addition, in HIV-positive patients, the sensitivity of tuberculin skin test decreases (68). Thus, in screening and detecting tuberculosis, a new diagnostic test based on specific antigens would be of great value. Moreover, most tuberculosis epidemiological studies, including tuberculin surveys, have been performed over limited geographical regions. The accessibility of the completely sequenced genome of *M. tuberculosis* has provided tools to detect bacterial antigens that are useful in the development of new reagents for tuberculosis diagnosis and controlling (66).

In Iran, tuberculosis surveillance is based on the conventional methods that have limited practical values. These methods consist of colony characteristics, growth temperature, and biochemical tests. These methods are widely used to identify mycobacteria isolates although they are labor-intensive and time-consuming and may sometimes remain inconclusive. These methods also cannot distinguish between new and old infections and cannot detect the source and route of infection. This issue is vital for diminishing tuberculosis, while determining the varieties of tuberculosis strains can be accomplished by DNA fingerprinting (69). At present, the challenge is to compile standardized molecular fingerprinting patterns originating from multi-centric, highly networked, and genotypic analysis in the databases for inter-laboratory utilization as well as for further references (70).

The technique most commonly employed in the molecular epidemiology of tuberculosis is strain typing by restriction fragment length polymorphism (RFLP), which is a technique based on the detection of differences in the numbers and locations of the insertion element IS6110 inside of the chromosomes of *M. tuberculosis* strains. However, this insertion element has low, but obvious, frequency of transposition so that RFLP patterns demonstrate a certain amount of instability (71). Overall, RFLP typing has more discriminatory power and is a valuable instrument for better comprehension of transmission and occurrence of micro-epidemics and source tracing (69).

A study from the northwest of Iran showed high average copy number of IS6110 per isolate, confirming the usefulness of this method for epidemiological studies without the necessity of using additional genetic markers (72). Finally, IS6110 fingerprinting is additionally restricted by the slow growth of *M. tuberculosis* because a viable culture is required to produce an accurate genotype. Subsequently, a few other genotyping methods have been developed, including variable-number tandem repeat typing (VNTR) (73), polymorphic GC-rich repetitive sequence typing (PGRS) (74), spacer oligonucleotide typing (spoligotyping) (75), and mycobacterial interspersed repetitive units typing (MIRU) (76). Comprehensive evaluation of the methods of genotyping *M. tuberculosis* has been clearly described in several studies; therefore, these techniques are not discussed in the present review.

12. Tuberculosis in People with AIDS

Despite the adoption of DOTS strategy by WHO, tuberculosis prevalence continues to increase globally, particularly in developing countries (69), which has been attributed to the emergence of drug-resistant tuberculosis and HIV pandemic (1). These two infections have a synergistic effect on each other. HIV infection, particularly advanced HIV infection (AIDS), is more critical than any other risk factors for the disease progression of recent or remotely acquired tuberculosis infection, both of which are major public health concern in numerous parts of the globe (23). Similarly, HIV infection is one of the most important risk factors promoting progression of latent tuberculosis infection to active tuberculosis disease in people with *M. tuberculosis* infection (77).

About ten million individuals are estimated to be co-infected with *M. tuberculosis*/HIV, and more than 90% of these infected people reside in developing countries (78). Among the patients with AIDS, tuberculosis kills one out of every three people. Before emerging highly active antiretroviral therapy, among the people co-infected with *M.*




Figure 4. Contribution of Patients or Health Systems to the Total Delay in the Treatment of Tuberculosis Patients

tuberculosis and HIV, the estimated risk of active tuberculosis relative to the patients with no other known risk factors for active tuberculosis was 113.0 times greater for HIV infection without AIDS and 170.0 times greater for AIDS (79). During the course of HIV infection, tuberculosis is the most important opportunistic infection that can happen at any point (80). Moreover, HIV-positive patients have high risk of transformation of latent tuberculosis into the active form, which makes patients more vulnerable to the development of adverse drug reactions (80). Compared with HIV-negative population, the clinical picture of tuberculosis is somewhat diverse in this group especially in the advanced phases of infection, which is shown as atypical radiologic findings such as mediastinal lymphadenopathy, pleural effusion, miliary pattern, and high incidence of extra pulmonary involvement (81).

There are many drug users in the country, including occasional users, mostly of opium; “but, intravenous heroin utilization is on the rise”. In addition, there are more than 10,000 HIV-positive individuals. A study carried out in 2002 showed that 11.4% of HIV-positive patients in Kermanshah Province were with tuberculosis (81). A multi-centric study evaluating the frequency of *M. tuberculosis* infection in the infected patients with HIV from Tehran in 2008 showed that almost 24% of patients with HIV/AIDS were also infected with *M. tuberculosis* (79). In another study from Khuzestan province in 2012, this rate was determined as 26% using PCR technique (82). These findings represent the requirement for preventive and diagnostic measures

as well as prompt treatment of this type of infection in the HIV-infected patients. The reported rate from India, a country with heavy load of AIDS, is 38.5% (83). The HIV prevalence in incident tuberculosis cases was reported to be 2.2% and the tuberculosis incidence and mortality among HIV-infected patients was less than 1% in this country (84).

13. Conclusions

In spite of the fact that the reported tuberculosis incidence rate in Iran has decreased during the last recent decades, tuberculosis control remains a need among public health policies. In the present review, the gathered data showed that a high proportion of tuberculosis cases are sensitive to antibiotics. However, to avoid the emergence of multidrug-resistant tuberculosis and to provide optimal treatment, susceptibility testing for all new cases is strongly recommended. In spite of the fact that anti-tuberculosis drug resistance is present in Iran, multidrug-resistant tuberculosis is considered to be prevalent. In addition, by enhancing the surgery system and increasing the number of multidrug-resistant tuberculosis patients qualified for surgery, it is hoped that a greater number of suspected patients will be cured in the country.

The results of several studies on the distribution pattern of strains in a few ethnic populaces have clarified the mechanism of transmission and factors related to the disease transmission (85, 86). The data gathered in the present

review will help us comprehend the dynamics of *M. tuberculosis* strains among different ethnic populations and geographic regions in Iran. Taken together, many studies have suggested that *M. tuberculosis* transmission is limited and restricted to close contact. Also, some genetic evolutions of *M. tuberculosis* which are in correlation with historic events remain to be investigated.

Developing programs to evaluate the conditions needed for screening the incidence and outbreaks of tuberculosis in different regions all over the country are recommended to identify the regions with high risk and performing precautionary measures, severely and precisely. Thus, it is important to consider the identification of tuberculosis, particularly in groups at risk, by early diagnosis in order to decrease the expense of the current methods, enhance the effectiveness of treatment, encourage preventive measures by using DOTS strategy, improved restriction of the entrance of opium drugs especially from the neighbor country Afghanistan, improved economic situation, and applying strict control on immigration and resolving social problems. Also, in order to prevent the transmission of drug-resistant tuberculosis from neighboring countries, new tuberculosis centers should be established near the borderlines to prohibit the travelling of patients and their long-term attendance.

Acknowledgments

We thank the staff of Tabriz and Urmia tuberculosis central laboratories for their generous cooperation. This study was supported by the Iran national science foundation for tuberculosis in human and cattle in Northwest of Iran (grant 843599).

Footnotes

Authors' Contribution: Abed Zahedi Bialvaei carried out the data collection and drafted the manuscript. Hossein Samadi Kafil participated in designing the study and drafting the manuscript. Mohammad Asgharzadeh participated in the design of the study. Manouchehr Nourazarian and Mohammad Aghazadeh participated in drafting the manuscript. All authors read and approved the final manuscript.

Conflict of Interest: We declare no conflict of interest for the authors of the present study.

Funding/Support: This study was granted by drug applied research center, Tabriz University of Medical Sciences, for a research project entitled "Tuberculosis status in Iran".

References

1. WHO . Global tuberculosis control: surveillance, planning, financing. WHO report 2007. Geneva, Switzerland: WHO; 2007.
2. Tabassum Siddiqui R, Waheed Akhtar M, Anver Qureshi J. The Presence and Copy Number of Insertion Sequence IS6110 in Mycobacterium tuberculosis Isolates from Pakistan. *Int J Agric Biol.* 2013;**15**(3).
3. Smith I. Mycobacterium tuberculosis pathogenesis and molecular determinants of virulence. *Clin Microbiol Rev.* 2003;**16**(3):463-96. [PubMed: 12857778].
4. Khazaei HA, Rezaei N, Bagheri GR, Dankoub MA, Shahryari K, Tahai A, et al. Epidemiology of tuberculosis in the Southeastern Iran. *Eur J Epidemiol.* 2005;**20**(10):879-83. doi: 10.1007/s10654-005-2152-y. [PubMed: 16283479].
5. Palwatwichai A. Tuberculosis in Thailand. *Respirology.* 2001;**6**(1):65-70. [PubMed: 11264766].
6. Tavakoli A, Safaei HG, Navvabakbar F, Salehi M, Bahremand A, Isfahani BN. Mutations in the rpoB Gene of Rifampin Resistant Mycobacterium tuberculosis Isolated in Isfahan by PCR-SSCP. *J Sci.* 2005;**16**(2):131-8.
7. WHO . Global tuberculosis report 2012. Geneva: WHO; 2012.
8. WHO . Tuberculosis Facts, 2009 Update. Geneva: World Health Organization; 2009.
9. WHO . Global health observatory data repository 2011. Geneva: WHO; 2011.
10. Babamahmoodi F, Alikhani A, Yazdani Charati J, Ghovvati A, Ahangarkani F, Delavarian L, et al. Clinical epidemiology and paraclinical findings in tuberculosis patients in north of Iran. *Biomed Res Int.* 2015;**2015**:381572. doi: 10.1155/2015/381572. [PubMed: 25695067].
11. WHO . Global Tuberculosis Report 2013 2013. Available from: <http://www.who.int/entity/tb/publications/globalreport/en/index.html>.
12. Ayatollahi J, Sharifi MR, Razmi H, Mahmoodiardekani B. The survey of tuberculosis patients in Yazd and Shiraz. *Q Res J Yazd.* 2010;**9**(1):1-7.
13. Filliol I, Driscoll JR, Van Soolingen D, Kreiswirth BN, Kremer K, Valetudie G, et al. Global distribution of Mycobacterium tuberculosis spoligotypes. *Emerg Infect Dis.* 2002;**8**(11):1347-9. doi: 10.3201/eid0811.020125. [PubMed: 12453368].
14. Ramazanadeh R, Sayhemiri K. Prevalence of Beijing family in Mycobacterium tuberculosis in world population: Systematic Review and Meta-Analysis. *Int J Mycobacteriol.* 2014;**3**(1):41-5. doi: 10.1016/j.ijmyco.2014.01.001. [PubMed: 26786221].
15. Merza MA, Farnia P, Salih AM, Masjedi MR, Velayati AA. First insight into the drug resistance pattern of Mycobacterium tuberculosis in Dohuk, Iraq: using spoligotyping and MIRU-VNTR to characterize multidrug resistant strains. *J Infect Public Health.* 2011;**4**(1):41-7. doi: 10.1016/j.jiph.2010.11.002. [PubMed: 21338958].
16. Farnia P, Masjedi MR, Mirsaeidi M, Mohammadi F, Jalleledin G, Vincent V, et al. Prevalence of Haarlem I and Beijing types of Mycobacterium tuberculosis strains in Iranian and Afghan MDR-TB patients. *J Infect.* 2006;**53**(5):331-6. doi: 10.1016/j.jinf.2005.12.020. [PubMed: 16476483].
17. Doustdar F, Khosravi AD, Farnia P, Bahrmann AR, Masjedi MR, Velayati AA. Mutations in rpoB gene and genotypes of rifampin resistant Mycobacterium tuberculosis isolates in Iran. *Tanaffos.* 2008;**7**(2):11-7.
18. Doroudchi M, Kremer K, Basiri EA, Kadivar MR, Van Soolingen D, Ghaderi AA. IS6110-RFLP and spoligotyping of Mycobacterium tuberculosis isolates in Iran. *Scand J Infect Dis.* 2000;**32**(6):663-8. [PubMed: 11200378].
19. Bialvaei AZ, Kafil HS, Asgharzadeh M. Role of Treatment Cost on Transmission of Multidrug-Resistant Tuberculosis Into Iran. *Clin Infect Dis.* 2015;**61**(6):1029-30. doi: 10.1093/cid/civ459. [PubMed: 26060290].
20. Tanveer M, Hasan Z, Siddiqui AR, Ali A, Kanji A, Ghebremichael S, et al. Genotyping and drug resistance patterns of M. tuberculosis strains in Pakistan. *BMC Infect Dis.* 2008;**8**:171. doi: 10.1186/1471-2334-8-171. [PubMed: 19108722].

21. Velayati AA, Farnia P, Mirsaeidi M, Reza Masjedi M. The most prevalent Mycobacterium tuberculosis superfamilies among Iranian and Afghan TB cases. *Scand J Infect Dis*. 2006;**38**(6-7):463-8. doi: [10.1080/00365540500504117](https://doi.org/10.1080/00365540500504117). [PubMed: [16798695](https://pubmed.ncbi.nlm.nih.gov/16798695/)].
22. WHO. Global tuberculosis control: surveillance, planning, financing. ;2003.
23. Shamaei M, Marjani M, Chitsaz E, Kazempour M, Esmaeili M, Farnia P, et al. First-line anti-tuberculosis drug resistance patterns and trends at the national TB referral center in Iran—eight years of surveillance. *Int J Infect Dis*. 2009;**13**(5):e236-40. doi: [10.1016/j.ijid.2008.11.027](https://doi.org/10.1016/j.ijid.2008.11.027). [PubMed: [19285897](https://pubmed.ncbi.nlm.nih.gov/19285897/)].
24. Farnia P, Masjedi MR, Varahram M, Mirsaeidi M, Ahmadi M, Khazampour M, et al. The recent-transmission of Mycobacterium tuberculosis strains among Iranian and Afghan relapse cases: a DNA-fingerprinting using RFLP and spoligotyping. *BMC Infect Dis*. 2008;**8**:109. doi: [10.1186/1471-2334-8-109](https://doi.org/10.1186/1471-2334-8-109). [PubMed: [18681980](https://pubmed.ncbi.nlm.nih.gov/18681980/)].
25. Asgharzadeh M, Kafil HS, Pourostadi M. Limited transmission of multidrug-resistant tuberculosis in East Azarbaijan, Iran. *Beni Suef Univ J Basic Appl Sci*. 2014;**3**(4):254-9. doi: [10.1016/j.bjbas.2014.11.004](https://doi.org/10.1016/j.bjbas.2014.11.004).
26. Asgharzadeh M, Shahbaban K, Samadi Kafil H, Rafi A. Use of DNA Fingerprinting in Identifying the Source Case of Tuberculosis in East Azarbaijan Province of Iran. *J Med Sci (Faisalabad)*. 2007;**7**(3):418-21. doi: [10.3923/jms.2007.418.421](https://doi.org/10.3923/jms.2007.418.421).
27. Merza MA, Farnia P, Tabarsi P, Khazampour M, Masjedi MR, Velayati AA. Anti-tuberculosis drug resistance and associated risk factors in a tertiary level TB center in Iran: a retrospective analysis. *J Infect Dev Ctries*. 2011;**5**(7):511-9. [PubMed: [21795819](https://pubmed.ncbi.nlm.nih.gov/21795819/)].
28. Velayati AA. Tuberculosis guide. Iran: Shahid Beheshti University Press, National Research Institute of Tuberculosis and Lung Diseases; 1996.
29. Masjedi MR, Tabatabaie D, Salek S. Tuberculosis guide. Tehran: Nat Res Inst Tuberc Lung Dis; 1997.
30. Bahrmand AR, Velayati AA, Bakayev VV. Treatment monitoring and prevalence of drug resistance in tuberculosis patients in Tehran. *Int J Tuberc Lung Dis*. 2000;**4**(6):544-9. [PubMed: [10864185](https://pubmed.ncbi.nlm.nih.gov/10864185/)].
31. Goble M, Iseman MD, Madsen LA, Waite D, Ackerson L, Horsburgh CJ. Treatment of 171 patients with pulmonary tuberculosis resistant to isoniazid and rifampin. *N Engl J Med*. 1993;**328**(8):527-32. doi: [10.1056/NEJM199302253280802](https://doi.org/10.1056/NEJM199302253280802). [PubMed: [8426619](https://pubmed.ncbi.nlm.nih.gov/8426619/)].
32. Valenzuela P, Valenzuela MT, Ponce J. Response to short-course chemotherapy of patients with initial resistance to antituberculosis drugs. *Bull Pan Am Health Organ*. 1988;**22**(2):175-83. [PubMed: [3048504](https://pubmed.ncbi.nlm.nih.gov/3048504/)].
33. Matsiota-Bernard P, Vrioni G, Marinis E. Characterization of rpoB mutations in rifampin-resistant clinical Mycobacterium tuberculosis isolates from Greece. *J Clin Microbiol*. 1998;**36**(1):20-3. [PubMed: [9431913](https://pubmed.ncbi.nlm.nih.gov/9431913/)].
34. Spindola de Miranda S, Kritski A, Filliol I, Mabilat C, Panteix G, Drouet E. Mutations in the rpoB gene of rifampicin-resistant Mycobacterium tuberculosis strains isolated in Brazil and France. *Mem Inst Oswaldo Cruz*. 2001;**96**(2):247-50. [PubMed: [11285505](https://pubmed.ncbi.nlm.nih.gov/11285505/)].
35. McCammon MT, Gillette JS, Thomas DP, Ramaswamy SV, Graviss EA, Kreiswirth BN, et al. Detection of rpoB mutations associated with rifampin resistance in Mycobacterium tuberculosis using denaturing gradient gel electrophoresis. *Antimicrob Agents Chemother*. 2005;**49**(6):2200-9. doi: [10.1128/AAC.49.6.2200-2209.2005](https://doi.org/10.1128/AAC.49.6.2200-2209.2005). [PubMed: [15917513](https://pubmed.ncbi.nlm.nih.gov/15917513/)].
36. Mohajeri P, Sadri H, Farahani A, Norozi B, Atashi S. Frequency of Mutations Associated with Rifampicin Resistance in Mycobacterium tuberculosis Strains Isolated from Patients in West of Iran. *Microb Drug Resist*. 2015;**21**(3):315-9. doi: [10.1089/mdr.2014.0075](https://doi.org/10.1089/mdr.2014.0075). [PubMed: [25526063](https://pubmed.ncbi.nlm.nih.gov/25526063/)].
37. Kim BJ, Hong SK, Lee KH, Yun YJ, Kim EC, Park YG, et al. Differential identification of Mycobacterium tuberculosis complex and nontuberculous mycobacteria by duplex PCR assay using the RNA polymerase gene (rpoB). *J Clin Microbiol*. 2004;**42**(3):1308-12. [PubMed: [15004105](https://pubmed.ncbi.nlm.nih.gov/15004105/)].
38. Ormerod LP. Multidrug-resistant tuberculosis (MDR-TB): epidemiology, prevention and treatment. *Br Med Bull*. 2005;**73**:74:17-24. doi: [10.1093/bmb/ldh047](https://doi.org/10.1093/bmb/ldh047). [PubMed: [15956357](https://pubmed.ncbi.nlm.nih.gov/15956357/)].
39. Mirsaeidi SM, Tabarsi P, Khoshnood K, Pooramiri MV, Rowhani-Rahbar A, Mansoori SD, et al. Treatment of multiple drug-resistant tuberculosis (MDR-TB) in Iran. *Int J Infect Dis*. 2005;**9**(6):317-22. doi: [10.1016/j.ijid.2004.09.012](https://doi.org/10.1016/j.ijid.2004.09.012). [PubMed: [16183321](https://pubmed.ncbi.nlm.nih.gov/16183321/)].
40. Nasiri MJ, Rezaei F, Zamani S, Darban-Sarokhalil D, Fooladi AA, Shojaei H, et al. Drug resistance pattern of Mycobacterium tuberculosis isolates from patients of five provinces of Iran. *Asian Pac J Trop Med*. 2014;**7**(3):193-6. doi: [10.1016/S1959-7645\(14\)60019-5](https://doi.org/10.1016/S1959-7645(14)60019-5). [PubMed: [24507638](https://pubmed.ncbi.nlm.nih.gov/24507638/)].
41. Ramazanadeh R, Farnia P, Amirmozafari N, Ghazi F, Ghadertotonchi Z, Kamran J, et al. Comparison between molecular epidemiology, geographical regions and drug resistance in Mycobacterium tuberculosis strains isolated from Iranian and Afghan patients. *Chemotherapy*. 2006;**52**(6):316-20. doi: [10.1159/000095971](https://doi.org/10.1159/000095971). [PubMed: [17008783](https://pubmed.ncbi.nlm.nih.gov/17008783/)].
42. Timmins GS, Deretic V. Mechanisms of action of isoniazid. *Mol Microbiol*. 2006;**62**(5):1220-7. doi: [10.1111/j.1365-2958.2006.05467.x](https://doi.org/10.1111/j.1365-2958.2006.05467.x). [PubMed: [17074073](https://pubmed.ncbi.nlm.nih.gov/17074073/)].
43. Yang Z, Durmaz R, Yang D, Gunal S, Zhang L, Foxman B, et al. Simultaneous detection of isoniazid, rifampin, and ethambutol resistance of Mycobacterium tuberculosis by a single multiplex allele-specific polymerase chain reaction (PCR) assay. *Diagn Microbiol Infect Dis*. 2005;**53**(3):201-8. doi: [10.1016/j.diagmicrobio.2005.06.007](https://doi.org/10.1016/j.diagmicrobio.2005.06.007). [PubMed: [16243477](https://pubmed.ncbi.nlm.nih.gov/16243477/)].
44. Hristea A, Otelea D, Paraschiv S, Macri A, Baicus C, Moldovan O, et al. Detection of Mycobacterium tuberculosis resistance mutations to rifampin and isoniazid by real-time PCR. *Indian J Med Microbiol*. 2010;**28**(3):211-6. doi: [10.4103/0255-0857.66474](https://doi.org/10.4103/0255-0857.66474). [PubMed: [20644308](https://pubmed.ncbi.nlm.nih.gov/20644308/)].
45. Guo H, Seet Q, Denkin S, Parsons L, Zhang Y. Molecular characterization of isoniazid-resistant clinical isolates of Mycobacterium tuberculosis from the USA. *J Med Microbiol*. 2006;**55**(Pt 11):527-31. doi: [10.1099/jmm.0.46718-0](https://doi.org/10.1099/jmm.0.46718-0). [PubMed: [17030912](https://pubmed.ncbi.nlm.nih.gov/17030912/)].
46. Mirsaeidi MS, Tabarsi P, Farnia P, Ebrahimi G, Morris MW, Masjedi MR, et al. Trends of drug resistant Mycobacterium tuberculosis in a tertiary tuberculosis center in Iran. *Saudi Med J*. 2007;**28**(4):544-50. [PubMed: [17457475](https://pubmed.ncbi.nlm.nih.gov/17457475/)].
47. Zaker Bostanabad S, Fateh A, Seyedi K, Abdolrahimi F, Karimi A, Hadizadeh Tasbiti A, et al. Frequency and molecular characterization of rifampicin-resistance in rpoB region of multiple drug resistance (MDR) isolates from tuberculosis patients in southern endemic region of Iran. *Iran J Biotechnol*. 2007;**5**(4):212-8.
48. Mohajeri P, Tavakoli A, Moghim S. Detection of mutation in codon 315 katG gene as a gene marker associated with isoniazid resistance, in mycobacterium tuberculosis strains isolated from patients in Isfahan and Tehran by PCR-RFLP method. *ZUMSJ*. 2009;**17**(66):29-40.
49. Heifets L, Lindholm-Levy P. Pyrazinamide sterilizing activity in vitro against semidormant Mycobacterium tuberculosis bacterial populations. *Am Rev Respir Dis*. 1992;**145**(5):1223-5. doi: [10.1164/ajrccm/145.5.1223](https://doi.org/10.1164/ajrccm/145.5.1223). [PubMed: [1586071](https://pubmed.ncbi.nlm.nih.gov/1586071/)].
50. Mitchison DA. The action of antituberculosis drugs in short-course chemotherapy. *Tubercle*. 1985;**66**(3):219-25. [PubMed: [3931319](https://pubmed.ncbi.nlm.nih.gov/3931319/)].
51. Marttila HJ, Marjamaki M, Vyshnevskaya E, Vyshnevskiy BI, Otten TF, Vasilyev AV, et al. pncA mutations in pyrazinamide-resistant Mycobacterium tuberculosis isolates from northwestern Russia. *Antimicrob Agents Chemother*. 1999;**43**(7):1764-6. [PubMed: [10390239](https://pubmed.ncbi.nlm.nih.gov/10390239/)].
52. Canetti G. Present aspects of bacterial resistance in tuberculosis. *Am Rev Respir Dis*. 1965;**92**(5):687-703. doi: [10.1164/arrd.1965.92.5.687](https://doi.org/10.1164/arrd.1965.92.5.687). [PubMed: [5321145](https://pubmed.ncbi.nlm.nih.gov/5321145/)].
53. World Health Organization. The WHO/IUATLD global project to anti-tuberculosis drug resistance surveillance 2000. Geneva, Switzerland: WHO; 2000.
54. Baran R, Ertan FU, Ozvaran K, Dolunay G. Primary drug resistant

- tuberculosis in children: A report from Turkey. *Tubercle Lung Dis*. 1994;**75**:12. doi: [10.1016/0962-8479\(94\)90723-4](https://doi.org/10.1016/0962-8479(94)90723-4).
55. Espinal MA, Laserson K, Camacho M, Fusheng Z, Kim SJ, Tlali RE, et al. Determinants of drug-resistant tuberculosis: analysis of 11 countries. *Int J Tuberc Lung Dis*. 2001;**5**(10):887-93. [PubMed: [11605880](https://pubmed.ncbi.nlm.nih.gov/11605880/)].
 56. Namaei MH, Sadeghian A, Naderinasab M, Ziaee M. Prevalence of primary drug resistant Mycobacterium tuberculosis in Mashhad, Iran. *Indian J Med Res*. 2006;**124**(1):77-80. [PubMed: [16926460](https://pubmed.ncbi.nlm.nih.gov/16926460/)].
 57. Becerra MC, Freeman J, Bayona J, Shin SS, Kim JY, Furin JJ, et al. Using treatment failure under effective directly observed short-course chemotherapy programs to identify patients with multidrug-resistant tuberculosis. *Int J Tuberc Lung Dis*. 2000;**4**(2):108-14. [PubMed: [10694087](https://pubmed.ncbi.nlm.nih.gov/10694087/)].
 58. Bostanabad SZ, Bahrmand A, Titov LP, Taghikhani M. Identification of mutations in the rpoB encoding the RNA polymerase beta subunit in rifampicine-resistant Mycobacterium tuberculosis strains from Iran. *Tuberk Toraks*. 2007;**55**(4):370-7. [PubMed: [18224505](https://pubmed.ncbi.nlm.nih.gov/18224505/)].
 59. Marjani M, Baghaei P, Tabarsi P, Shamaei M, Mansouri D, Masjedi MR, et al. Drug resistance pattern and outcome of treatment in recurrent episodes of tuberculosis. *East Mediterr Health J*. 2012;**18**(9):957-61. [PubMed: [23057389](https://pubmed.ncbi.nlm.nih.gov/23057389/)].
 60. Surucuoğlu S, Ozkutuk N, Celik P, Gazi H, Dinc G, Kurutepe S, et al. Drug-resistant pulmonary tuberculosis in western Turkey: prevalence, clinical characteristics and treatment outcome. *Ann Saudi Med*. 2005;**25**(4):313-8. [PubMed: [16212125](https://pubmed.ncbi.nlm.nih.gov/16212125/)].
 61. Masjedi MR, Farnia P, Sorooch S, Pooramiri MV, Mansoori SD, Zarifi AZ, et al. Extensively drug-resistant tuberculosis: 2 years of surveillance in Iran. *Clin Infect Dis*. 2006;**43**(7):841-7. doi: [10.1086/507542](https://doi.org/10.1086/507542). [PubMed: [16941364](https://pubmed.ncbi.nlm.nih.gov/16941364/)].
 62. Asgharzadeh M, Kafil HS, Roudsary AA, Hanifi GR. Tuberculosis transmission in Northwest of Iran: using MIRU-VNTR, ETR-VNTR and IS6110-RFLP methods. *Infect Genet Evol*. 2011;**11**(1):124-31. doi: [10.1016/j.meegid.2010.09.013](https://doi.org/10.1016/j.meegid.2010.09.013). [PubMed: [20951237](https://pubmed.ncbi.nlm.nih.gov/20951237/)].
 63. Bialvaei AZ, Samadi Kafil H. Colistin, mechanisms and prevalence of resistance. *Curr Med Res Opin*. 2015;**31**(4):707-21. doi: [10.1185/03007995.2015.1018989](https://doi.org/10.1185/03007995.2015.1018989). [PubMed: [25697677](https://pubmed.ncbi.nlm.nih.gov/25697677/)].
 64. Lonnroth K, Ravignione M. Global epidemiology of tuberculosis: prospects for control. *Semin Respir Crit Care Med*. 2008;**29**(5):481-91. doi: [10.1055/s-0028-1085700](https://doi.org/10.1055/s-0028-1085700). [PubMed: [18810682](https://pubmed.ncbi.nlm.nih.gov/18810682/)].
 65. World Health Organization. Diagnostic and Treatment Delay in Tuberculosis, 2006-2006. Available from: <http://applications.emro.who.int/dsaf/dsa710.pdf>.
 66. Bai Y, Xue Y, Gao H, Wang L, Ding T, Bai W, et al. Expression and purification of Mycobacterium tuberculosis ESAT-6 and MPT64 fusion protein and its immunoprophylactic potential in mouse model. *Protein Expr Purif*. 2008;**59**(2):189-96. doi: [10.1016/j.pep.2007.11.016](https://doi.org/10.1016/j.pep.2007.11.016). [PubMed: [18378164](https://pubmed.ncbi.nlm.nih.gov/18378164/)].
 67. Hadadi A, Rasoolinejad M, Davoudi S, Nikdel M, Rasteh M. Clinical characteristics of pulmonary tuberculosis in patients with HIV/AIDS: a case-control study. *Tehran Univ Med J TUMS Public*. 2006;**64**(5):87-95.
 68. Converse PJ, Jones SL, Astemborski J, Vlahov D, Graham NM. Comparison of a tuberculin interferon-gamma assay with the tuberculin skin test in high-risk adults: effect of human immunodeficiency virus infection. *J Infect Dis*. 1997;**176**(1):144-50. [PubMed: [9207360](https://pubmed.ncbi.nlm.nih.gov/9207360/)].
 69. Asgharzadeh M, Kafil HS, Khakpour M. Comparison of mycobacterial interspersed repetitive unit-variable number tandem repeat and IS6110-RFLP methods in identifying epidemiological links in patients with tuberculosis in Northwest of Iran. *Ann Microbiol*. 2008;**58**:333. doi: [10.1007/BF03175339](https://doi.org/10.1007/BF03175339).
 70. Asgharzadeh M, Samadi Kafil H. Current trends in molecular epidemiology studies of Mycobacterium tuberculosis. *Biotechnol Mol Biol Rev*. 2007;**2**(5):108-15.
 71. Caminero JA, Pena MJ, Campos-Herrero MI, Rodriguez JC, Garcia I, Cabrera P, et al. Epidemiological evidence of the spread of a Mycobacterium tuberculosis strain of the Beijing genotype on Gran Canaria Island. *Am J Respir Crit Care Med*. 2001;**164**(7):1165-70. doi: [10.1164/ajrccm.164.7.2101031](https://doi.org/10.1164/ajrccm.164.7.2101031). [PubMed: [11673204](https://pubmed.ncbi.nlm.nih.gov/11673204/)].
 72. Asgharzadeh M, Yousefi S, Nahaei MR, Akhi MT, Ansarian K, Samadi Kafil H. IS6110 Fingerprinting of Mycobacterium tuberculosis Strains Isolated from Northwest of Iran. *Res J Microbiol*. 2007;**2**(12):940-6. doi: [10.3923/jm.2007.940.946](https://doi.org/10.3923/jm.2007.940.946).
 73. Magdalena J, Vachee A, Supply P, Loch C. Identification of a new DNA region specific for members of Mycobacterium tuberculosis complex. *J Clin Microbiol*. 1998;**36**(4):937-43. [PubMed: [9542912](https://pubmed.ncbi.nlm.nih.gov/9542912/)].
 74. Chaves F, Yang Z, el Hajj H, Alonso M, Burman WJ, Eisenach KD, et al. Usefulness of the secondary probe pTBN12 in DNA fingerprinting of Mycobacterium tuberculosis. *J Clin Microbiol*. 1996;**34**(5):1118-23. [PubMed: [8727887](https://pubmed.ncbi.nlm.nih.gov/8727887/)].
 75. Kamerbeek J, Schouls L, Kolk A, van Agterveld M, van Soolingen D, Kuijper S, et al. Simultaneous detection and strain differentiation of Mycobacterium tuberculosis for diagnosis and epidemiology. *J Clin Microbiol*. 1997;**35**(4):907-14. [PubMed: [9157152](https://pubmed.ncbi.nlm.nih.gov/9157152/)].
 76. Mazaris E, Lesjean S, Banuls AL, Gilbert M, Vincent V, Gicquel B, et al. High-resolution minisatellite-based typing as a portable approach to global analysis of Mycobacterium tuberculosis molecular epidemiology. *Proc Natl Acad Sci U S A*. 2001;**98**(4):1901-6. doi: [10.1073/pnas.98.4.1901](https://doi.org/10.1073/pnas.98.4.1901). [PubMed: [11172048](https://pubmed.ncbi.nlm.nih.gov/11172048/)].
 77. Swaminathan S, Narendran G. HIV and tuberculosis in India. *J Biosci*. 2008;**33**(4):527. doi: [10.1007/s12038-008-0071-2](https://doi.org/10.1007/s12038-008-0071-2).
 78. Dye C, Scheele S, Dolin P, Pathania V, Ravignione MC. Consensus statement. Global burden of tuberculosis: estimated incidence, prevalence, and mortality by country. WHO Global Surveillance and Monitoring Project. *JAMA*. 1999;**282**(7):677-86. [PubMed: [10517722](https://pubmed.ncbi.nlm.nih.gov/10517722/)].
 79. Jam S, Sabzvari D, SeyedAlinaghi S, Fattahi F, Jabbari H, Mohraz M. Frequency of Mycobacterium tuberculosis infection among Iranian patients with HIV/AIDS by PPD test. *Acta Med Iran*. 2010;**48**(1):67-71. [PubMed: [21137673](https://pubmed.ncbi.nlm.nih.gov/21137673/)].
 80. Tabarsi P, Mirsaeidi SM, Amiri M, Mansouri SD, Masjedi MR, Velayati AA. Clinical and laboratory profile of patients with tuberculosis/HIV coinfection at a national referral centre: a case series. *East Mediterr Health J*. 2008;**14**(2):283-91. [PubMed: [18561719](https://pubmed.ncbi.nlm.nih.gov/18561719/)].
 81. Mansoori D, Alaei K, Alaei A. Prevalence of clinical tuberculosis in HIV infected patients from Kermanshah Province, Iran. *Tanaffos*. 2002;**1**(2):27-33.
 82. Khosravi AD, Alavi SM, Hashemzade M, Abasi E, Seghatoleslami S. The relative frequency of Mycobacterium tuberculosis and Mycobacterium avium infections in HIV positive patients, Ahvaz, Iran. *Asian Pac J Trop Med*. 2012;**5**(1):71-4. doi: [10.1016/S1995-7645\(11\)60249-6](https://doi.org/10.1016/S1995-7645(11)60249-6). [PubMed: [22182648](https://pubmed.ncbi.nlm.nih.gov/22182648/)].
 83. Steinbrook R. Tuberculosis and HIV in India. *N Engl J Med*. 2007;**356**(12):1198-9. doi: [10.1056/NEJMp078049](https://doi.org/10.1056/NEJMp078049). [PubMed: [17377155](https://pubmed.ncbi.nlm.nih.gov/17377155/)].
 84. Dye C. Global epidemiology of tuberculosis. *Lancet*. 2006;**367**(9514):938-40. doi: [10.1016/s0140-6736\(06\)68384-0](https://doi.org/10.1016/s0140-6736(06)68384-0).
 85. Asgharzadeh M, Samadi Kafil H, Pourostadi M, Asadi Faezi N, Rashedi J, Mahdavi-pour B. Strain differentiation of Mycobacterium tuberculosis for epidemiology in northwest of Iran. *Cell Mol Biol (Noisy-le-grand)*. 2016;**62**(8):15-20. [PubMed: [27545209](https://pubmed.ncbi.nlm.nih.gov/27545209/)].
 86. Pourostadi M, Rashedi J, Mahdavi Poor B, Samadi Kafil H, Shirazi S, Asgharzadeh M. Molecular Diversity of Mycobacterium tuberculosis Strains in Northwestern Iran. *Jundishapur J Microbiol*. 2016;**9**(9):ee35520. doi: [10.5812/jjm.35520](https://doi.org/10.5812/jjm.35520). [PubMed: [27800145](https://pubmed.ncbi.nlm.nih.gov/27800145/)].